385 related articles for article (PubMed ID: 30259750)
21. Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.
Sayour EJ; De Leon G; Pham C; Grippin A; Kemeny H; Chua J; Huang J; Sampson JH; Sanchez-Perez L; Flores C; Mitchell DA
Oncoimmunology; 2017; 6(1):e1256527. PubMed ID: 28197373
[TBL] [Abstract][Full Text] [Related]
22. RNA aggregates harness the danger response for potent cancer immunotherapy.
Mendez-Gomez HR; DeVries A; Castillo P; von Roemeling C; Qdaisat S; Stover BD; Xie C; Weidert F; Zhao C; Moor R; Liu R; Soni D; Ogando-Rivas E; Chardon-Robles J; McGuiness J; Zhang D; Chung MC; Marconi C; Michel S; Barpujari A; Jobin GW; Thomas N; Ma X; Campaneria Y; Grippin A; Karachi A; Li D; Sahay B; Elliott L; Foster TP; Coleman KE; Milner RJ; Sawyer WG; Ligon JA; Simon E; Cleaver B; Wynne K; Hodik M; Molinaro AM; Guan J; Kellish P; Doty A; Lee JH; Massini T; Kresak JL; Huang J; Hwang EI; Kline C; Carrera-Justiz S; Rahman M; Gatica S; Mueller S; Prados M; Ghiaseddin AP; Silver NL; Mitchell DA; Sayour EJ
Cell; 2024 May; 187(10):2521-2535.e21. PubMed ID: 38697107
[TBL] [Abstract][Full Text] [Related]
23. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U
Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205
[TBL] [Abstract][Full Text] [Related]
24. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
[TBL] [Abstract][Full Text] [Related]
25. Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy.
Guan X; Lin L; Chen J; Hu Y; Sun P; Tian H; Maruyama A; Chen X
J Control Release; 2019 Jan; 293():104-112. PubMed ID: 30476528
[TBL] [Abstract][Full Text] [Related]
26. Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer.
Wang P; Zhong W; Huang Q; Zhu Y; Chen L; Ye K
ACS Biomater Sci Eng; 2024 May; 10(5):3136-3147. PubMed ID: 38663028
[TBL] [Abstract][Full Text] [Related]
27. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma.
Insug O; Ku G; Ertl HC; Blaszczyk-Thurin M
Anticancer Res; 2002; 22(2A):613-21. PubMed ID: 12014629
[TBL] [Abstract][Full Text] [Related]
28. Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response.
Yu X; Dai Y; Zhao Y; Qi S; Liu L; Lu L; Luo Q; Zhang Z
Nat Commun; 2020 Feb; 11(1):1110. PubMed ID: 32111828
[TBL] [Abstract][Full Text] [Related]
29. Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma.
Wildes TJ; Grippin A; Dyson KA; Wummer BM; Damiani DJ; Abraham RS; Flores CT; Mitchell DA
Clin Cancer Res; 2018 Aug; 24(16):3955-3966. PubMed ID: 29712687
[No Abstract] [Full Text] [Related]
30. Tumor Lysate-Loaded Lipid Hybrid Nanovaccine Collaborated with an Immune Checkpoint Antagonist for Combination Immunotherapy.
Hu X; Wu T; Qin X; Qi Y; Qiao Q; Yang C; Zhang Z
Adv Healthc Mater; 2019 Jan; 8(1):e1800837. PubMed ID: 30506847
[TBL] [Abstract][Full Text] [Related]
31. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
Front Immunol; 2018; 9():727. PubMed ID: 29910795
[TBL] [Abstract][Full Text] [Related]
32. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
[TBL] [Abstract][Full Text] [Related]
33. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
[TBL] [Abstract][Full Text] [Related]
35. Synthetic multiepitope neoantigen DNA vaccine for personalized cancer immunotherapy.
Yang X; Fan J; Wu Y; Ma Z; Huang J; Zhang Y; Zhou Z; Mo F; Liu X; Yuan H; Xu Y; Pan L; Chen S
Nanomedicine; 2021 Oct; 37():102443. PubMed ID: 34303839
[TBL] [Abstract][Full Text] [Related]
36. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
37. High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T
Löhr M; Freitag B; Technau A; Krauss J; Monoranu CM; Rachor J; Lutz MB; Hagemann C; Kessler AF; Linsenmann T; Wölfl M; Ernestus RI; Engelhardt S; Gelbrich G; Schlegel PG; Eyrich M
Cancer Immunol Immunother; 2018 Oct; 67(10):1545-1558. PubMed ID: 30054667
[TBL] [Abstract][Full Text] [Related]
38. Surgical Tumor-Derived Personalized Photothermal Vaccine Formulation for Cancer Immunotherapy.
Ye X; Liang X; Chen Q; Miao Q; Chen X; Zhang X; Mei L
ACS Nano; 2019 Mar; 13(3):2956-2968. PubMed ID: 30789699
[TBL] [Abstract][Full Text] [Related]
39. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
Cavalcante L; Chowdhary A; Sosman JA; Chandra S
Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
[TBL] [Abstract][Full Text] [Related]
40. A tumor microenvironment responsive biodegradable CaCO
Liu Y; Pan Y; Cao W; Xia F; Liu B; Niu J; Alfranca G; Sun X; Ma L; de la Fuente JM; Song J; Ni J; Cui D
Theranostics; 2019; 9(23):6867-6884. PubMed ID: 31660074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
